3682-19-7

Basic information

• Product Name: 4-Nitrophthalhydrazide
• Synonyms: 2,3-dihydro-6-nitro-4-phthalazinedione;6-nitrophthalhydrazide;2,3-DIHYDRO-6-NITRO-1,4-PHTHALAZINEDIONE;AKOS 92051;4-NITROPHTHALHYDRAZIDE;1,4-Phthalazinedione, 2,3-dihydro-6-nitro.;4-NITROPHTHALIC HYDRAZIDE,98.0+%(LC)(T);4-Nitrophthalic Hydrazide
• CAS NO: 3682-19-7
• Molecular Formula: C₈H₅N₃O₄
• Molecular Weight: 207.14
• Mol File: 3682-19-7.mol
• Article Data: 9

Chemical Properties

• Melting Point: 300°C(dec.)(lit.)
• Boiling Point: 626.8 °C at 760 mmHg
• Flash Point: 332.9 °C
• Appearance: light yellow powder
• Density: 1.555g/cm³
• Vapor Pressure: 2.65E-16mmHg at 25°C
• Refractive Index: 1.628
• PKA: 9.30±0.20(Predicted)
• CAS DataBase Reference: 4-Nitrophthalhydrazide(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Nitrophthalhydrazide(3682-19-7)
• EPA Substance Registry System: 4-Nitrophthalhydrazide(3682-19-7)

Safety Data

• RTECS: TH8895000
• Hazardous Substances Data: 3682-19-7(Hazardous Substances Data)

Usage

Air & Water Reactions

Insoluble in water.

Reactivity Profile

A nitrated amine derivative. Amines are chemical bases. They neutralize acids to form salts plus water. These acid-base reactions are exothermic. The amount of heat that is evolved per mole of amine in a neutralization is largely independent of the strength of the amine as a base. Amines may be incompatible with isocyanates, halogenated organics, peroxides, phenols (acidic), epoxides, anhydrides, and acid halides. Flammable gaseous hydrogen is generated by amines in combination with strong reducing agents, such as hydrides.

Fire Hazard

Flash point data for 4-Nitrophthalhydrazide are not available; however, 4-Nitrophthalhydrazide is probably combustible.

InChI:InChI=1/C8H5N3O4/c12-7-5-2-1-4(11(14)15)3-6(5)8(13)10-9-7/h1-3H,(H,9,12)(H,10,13)

Upstream product

• 5466-84-2 4-nitrophthalic anhydride 
• 610-27-5 4-nitrophthalic acid 
• 3069-13-4 2,3-diacetyl-2,3-dihydro-phthalazine-1,4-dione 
• 1445-69-8 2,3-dihydrophthalazine-1,4-dione 
• 88-99-3 benzene-1,2-dicarboxylic acid 
• 67081-02-1 5-nitro-3H-isobenzofuran-1-one 
• 89-40-7 4-nitrophthalimide 

Downstream Products

• 3682-14-2 isoluminol 
• 610-27-5 4-nitrophthalic acid 
• 302-01-2 hydrazine 
• 178309-12-1 1-Chloro-4-(3-chloro-4-methoxybenzyl)amino-6-nitrophthalazine 

Relevant articles and documents

INHIBITORS OF CYCLIN-DEPENDENT KINASES

Provided herein are compounds which are inhibitors of cyclin-dependent kinases (CDKs), pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.

Method for preparing isoluminol from phthalylhydrazine used as raw material

The invention belongs to the technical field of chemical synthesis and particularly relates to a method for preparing isoluminol from phthalylhydrazine used as a raw material. According to the method for preparing the isoluminol, the phthalylhydrazine is used as the raw material and reacts with an acetylation reagent, and diacetyl phthalylhydrazine is obtained; the diacetyl phthalylhydrazine reacts with a nitroso compound, and nitroso diacetyl phthalylhydrazine is obtained; then nitroso phthalylhydrazine is obtained through a deacetylation reaction; the isoluminol is obtained through a reduction reaction. With the adoption of the method, a large quantity of phthalylhydrazine byproducts in the existing Gabriel amine synthesis method are sufficiently utilized as the raw material, the raw material is cheap and easy to obtain, meanwhile, the synthesis process is simple, reaction conditions are mild, the yield of isoluminol products is higher, reactions are simple to operate, the application range is wider, and industrial production requirements of the products can be fully met.

Methods of inhibiting BTK and SYK protein kinases

Methods of inhibiting a tyrosine kinase wherein said tyrosine kinase is BTK or SYK comprising administering to a patient in need thereof a therapeutically effective amount of a compound according to formula I are disclosed. The compounds are useful for treating auto-immune and inflammatory diseases.